StressMarq Biosciences Inc. PCT Patent Application for a Novel Antibody Therapeutic Candidate to Combat Parkinson's Disease is Published

Thursday, March 7, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

The early stage pre-clinical therapeutic candidate interferes with toxic alpha synuclein aggregation, a key Parkinson's Disease target

VICTORIA, British Columbia, March 7, 2019 /PRNewswire-PRWeb/ -- StressMarq Biosciences Inc., a research and development

company specializing in manufacturing neurological and cellular stress research tools today announced the publication of its recent PCT patent application describing a potential therapeutic monoclonal antibody for Parkinson's Disease treatment. The antibody, still at a pre-clinical stage of development, moves the company into the drug discovery field.

The antibody was shown to neutralize the ability of alpha synuclein, a key therapeutic target in Parkinson's Disease, to generate toxic fibrils in rat primary cells. Early stage data also suggests an ability to significantly reduce Tau aggregation, a therapeutic target in Alzheimer's Disease. Antibodies have recently gained significant interest as therapeutic agents due to their high specificity and low toxicity profiles, differentiating them from most other drug candidates such as small molecules. The PCT application describes a new situation where a therapeutic antibody candidate appears to provide neutralizing capabilities against more than one neurological disease, although all data is still pre-clinical at this time and most of the data surrounds Parkinson's Disease.

"The situation we have is quite remarkable. While specifically targeting a complex set of alpha synuclein oligomeric forms in order to make state-of-the art research tools, we have identified an antibody that appears to have not just neutralizing capabilities, but structure-based binding to multiple disease targets. This opens up the possibility that this therapeutic antibody candidate could treat not just one, but two or more prevalent neurological diseases with similar protein fibril structures. We look forward to seeing how this exciting platform will continue to develop," said Ariel Louwrier, President and CEO of StressMarq.

About StressMarq Biosciences Inc.

StressMarq Biosciences is Canadian privately-held corporation based in Victoria BC that specializes in the development and manufacture of high quality research tools for the academic, pharma, and biotechnology industries. Recently it has emerged as the sole world-wide manufacturer of a variety of precursor and fibrilized protein preparations including alpha, beta and gamma synuclein, tau and transthyretin - implicated in neurological diseases including Parkinson's and Alzheimer's Diseases. The company also develops, manufactures and sells antibodies, small molecules and ELISA kits for research purposes. Additional information can be found on StressMarq's website at http://www.stressmarq.com

 

SOURCE StressMarq Biosciences Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store